T1	Participants 373 474	patients with chronic schizophrenia treated with monotherapy of haloperidol, risperidone or clozapine
T2	Participants 627 662	patients with chronic schizophrenia
T3	Participants 704 780	51 patients with chronic schizophrenia with ages ranging from 20 to 45 years
T4	Participants 782 892	All participants were inpatients, in the active phase of illness, and met DSM-IV-TR criteria for schizophrenia
T5	Participants 1478 1529	schizophrenic patients being treated with clozapine
